 Shelley Miyamoto
Concepts (385)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 39 | 2025 | 754 | 5.230 |
Why?
| | Heart Defects, Congenital | 15 | 2024 | 842 | 2.570 |
Why?
| | Heart Failure | 19 | 2025 | 2236 | 2.570 |
Why?
| | Cardiomyopathy, Dilated | 14 | 2025 | 385 | 2.470 |
Why?
| | Heart Ventricles | 15 | 2022 | 788 | 2.370 |
Why?
| | Heart-Lung Transplantation | 2 | 2025 | 14 | 1.930 |
Why?
| | MicroRNAs | 9 | 2025 | 692 | 1.910 |
Why?
| | Circulating MicroRNA | 3 | 2023 | 24 | 1.600 |
Why?
| | Cardiomyopathies | 7 | 2023 | 350 | 1.550 |
Why?
| | Disease Management | 4 | 2025 | 628 | 1.540 |
Why?
| | Lung Transplantation | 2 | 2025 | 313 | 1.530 |
Why?
| | Myocardium | 8 | 2021 | 1002 | 1.440 |
Why?
| | Societies, Medical | 2 | 2025 | 820 | 1.410 |
Why?
| | Hypoplastic Left Heart Syndrome | 6 | 2017 | 121 | 1.350 |
Why?
| | Myocytes, Cardiac | 8 | 2025 | 526 | 1.320 |
Why?
| | Milrinone | 2 | 2021 | 29 | 1.190 |
Why?
| | Ventricular Remodeling | 4 | 2021 | 266 | 1.150 |
Why?
| | Child | 65 | 2025 | 21935 | 1.040 |
Why?
| | Graft Rejection | 9 | 2025 | 624 | 1.010 |
Why?
| | Cardiomyopathy, Hypertrophic | 3 | 2023 | 142 | 0.960 |
Why?
| | Ventricular Function, Right | 2 | 2018 | 285 | 0.950 |
Why?
| | Heart Diseases | 5 | 2023 | 346 | 0.930 |
Why?
| | Ventricular Function, Left | 6 | 2024 | 534 | 0.890 |
Why?
| | Graft Survival | 8 | 2025 | 535 | 0.750 |
Why?
| | Infant | 33 | 2025 | 9465 | 0.700 |
Why?
| | Child, Preschool | 40 | 2025 | 11074 | 0.690 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 127 | 0.630 |
Why?
| | Down-Regulation | 4 | 2025 | 657 | 0.630 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 91 | 0.620 |
Why?
| | Phosphodiesterase 3 Inhibitors | 2 | 2016 | 14 | 0.620 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 1587 | 0.610 |
Why?
| | Fever | 1 | 2020 | 306 | 0.600 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.590 |
Why?
| | Humans | 87 | 2025 | 137585 | 0.550 |
Why?
| | Steroids | 2 | 2015 | 167 | 0.530 |
Why?
| | Hemodynamics | 6 | 2015 | 1113 | 0.520 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2017 | 145 | 0.520 |
Why?
| | Female | 64 | 2025 | 73304 | 0.490 |
Why?
| | Male | 59 | 2025 | 67762 | 0.490 |
Why?
| | Fontan Procedure | 4 | 2023 | 180 | 0.490 |
Why?
| | Histone Deacetylases | 1 | 2017 | 215 | 0.480 |
Why?
| | Case-Control Studies | 9 | 2025 | 3556 | 0.440 |
Why?
| | Echocardiography | 6 | 2021 | 642 | 0.440 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 890 | 0.400 |
Why?
| | Biomarkers | 9 | 2021 | 4149 | 0.400 |
Why?
| | Adolescent | 37 | 2025 | 21513 | 0.390 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 553 | 0.390 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 45 | 0.390 |
Why?
| | Waiting Lists | 2 | 2013 | 266 | 0.370 |
Why?
| | Cardiovascular Diseases | 2 | 2022 | 2111 | 0.370 |
Why?
| | Animals, Newborn | 5 | 2021 | 844 | 0.370 |
Why?
| | Calcium-Binding Proteins | 3 | 2021 | 218 | 0.360 |
Why?
| | Phosphoric Diester Hydrolases | 3 | 2016 | 46 | 0.360 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2017 | 24 | 0.360 |
Why?
| | Recovery of Function | 2 | 2015 | 653 | 0.360 |
Why?
| | Dexmedetomidine | 3 | 2017 | 43 | 0.350 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2607 | 0.350 |
Why?
| | Age Factors | 10 | 2024 | 3295 | 0.340 |
Why?
| | Connexin 43 | 2 | 2025 | 32 | 0.330 |
Why?
| | Phenotype | 4 | 2023 | 3196 | 0.320 |
Why?
| | Primary Graft Dysfunction | 1 | 2009 | 32 | 0.310 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 617 | 0.310 |
Why?
| | Cardiolipins | 3 | 2021 | 85 | 0.310 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2010 | 301 | 0.300 |
Why?
| | Reoviridae Infections | 1 | 2009 | 54 | 0.300 |
Why?
| | Rats, Sprague-Dawley | 5 | 2021 | 2486 | 0.290 |
Why?
| | Granuloma, Plasma Cell | 1 | 2008 | 13 | 0.290 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 66 | 0.290 |
Why?
| | Retrospective Studies | 23 | 2024 | 15657 | 0.290 |
Why?
| | Everolimus | 2 | 2025 | 91 | 0.290 |
Why?
| | Prospective Studies | 11 | 2021 | 7604 | 0.290 |
Why?
| | American Heart Association | 3 | 2024 | 306 | 0.280 |
Why?
| | Myocarditis | 1 | 2009 | 100 | 0.280 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 117 | 0.280 |
Why?
| | Cardiac Catheterization | 4 | 2017 | 530 | 0.280 |
Why?
| | Signal Transduction | 3 | 2017 | 5079 | 0.270 |
Why?
| | Coronary Artery Disease | 4 | 2024 | 698 | 0.270 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 346 | 0.270 |
Why?
| | Tacrolimus | 2 | 2025 | 199 | 0.270 |
Why?
| | Ventricular Outflow Obstruction | 2 | 2022 | 43 | 0.260 |
Why?
| | Kidney Transplantation | 2 | 2023 | 708 | 0.260 |
Why?
| | Treatment Outcome | 16 | 2025 | 10811 | 0.260 |
Why?
| | Phosphorylation | 4 | 2021 | 1759 | 0.250 |
Why?
| | Databases, Factual | 5 | 2016 | 1357 | 0.250 |
Why?
| | Calcium | 3 | 2021 | 1199 | 0.250 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 87 | 0.230 |
Why?
| | Infant, Newborn | 10 | 2021 | 6079 | 0.230 |
Why?
| | Coronary Vessels | 2 | 2017 | 248 | 0.230 |
Why?
| | Fibrosis | 2 | 2017 | 552 | 0.220 |
Why?
| | Heart-Assist Devices | 4 | 2019 | 552 | 0.220 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 746 | 0.210 |
Why?
| | Allografts | 1 | 2024 | 146 | 0.210 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2023 | 10 | 0.210 |
Why?
| | Heart | 3 | 2022 | 655 | 0.200 |
Why?
| | Pulmonary Artery | 1 | 2009 | 1086 | 0.200 |
Why?
| | Sarcomeres | 1 | 2023 | 96 | 0.200 |
Why?
| | Fibroma | 1 | 2022 | 21 | 0.190 |
Why?
| | Cyclic AMP | 2 | 2014 | 234 | 0.190 |
Why?
| | Data Accuracy | 1 | 2022 | 65 | 0.190 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2024 | 382 | 0.190 |
Why?
| | Heart Neoplasms | 1 | 2022 | 50 | 0.190 |
Why?
| | Barth Syndrome | 1 | 2021 | 8 | 0.190 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 41 | 0.180 |
Why?
| | Transcriptome | 2 | 2021 | 971 | 0.180 |
Why?
| | Focal Adhesions | 1 | 2021 | 44 | 0.180 |
Why?
| | Longevity | 1 | 2022 | 165 | 0.180 |
Why?
| | RNA-Binding Proteins | 1 | 2025 | 422 | 0.180 |
Why?
| | Fetofetal Transfusion | 1 | 2021 | 26 | 0.180 |
Why?
| | Cytokines | 1 | 2009 | 2085 | 0.170 |
Why?
| | Cardiopulmonary Bypass | 3 | 2022 | 209 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2019 | 4193 | 0.170 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 12 | 0.170 |
Why?
| | Probenecid | 1 | 2020 | 8 | 0.170 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 66 | 0.170 |
Why?
| | Amniotic Fluid | 1 | 2021 | 96 | 0.170 |
Why?
| | Heart Rate | 3 | 2023 | 822 | 0.170 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2031 | 0.170 |
Why?
| | Serum | 2 | 2018 | 59 | 0.170 |
Why?
| | Young Adult | 13 | 2024 | 13209 | 0.170 |
Why?
| | Isoproterenol | 2 | 2018 | 113 | 0.170 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 124 | 0.170 |
Why?
| | Hypertension, Pulmonary | 3 | 2017 | 1910 | 0.160 |
Why?
| | Apoptosis | 1 | 2009 | 2553 | 0.160 |
Why?
| | ROC Curve | 3 | 2017 | 554 | 0.160 |
Why?
| | Time Factors | 7 | 2024 | 6828 | 0.160 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2020 | 132 | 0.160 |
Why?
| | Risk Factors | 11 | 2024 | 10388 | 0.160 |
Why?
| | Atrial Function, Right | 1 | 2019 | 12 | 0.160 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 38 | 0.150 |
Why?
| | Troponin I | 1 | 2019 | 81 | 0.150 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 89 | 0.150 |
Why?
| | Fatty Acids | 1 | 2021 | 443 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 37 | 0.150 |
Why?
| | Tissue Donors | 3 | 2016 | 425 | 0.150 |
Why?
| | Mitochondria, Heart | 2 | 2020 | 102 | 0.140 |
Why?
| | Heart Atria | 1 | 2019 | 137 | 0.140 |
Why?
| | Lymphoproliferative Disorders | 2 | 2025 | 57 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 22 | 0.140 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 305 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 570 | 0.140 |
Why?
| | Rats | 5 | 2025 | 5647 | 0.140 |
Why?
| | Animals | 11 | 2025 | 36940 | 0.140 |
Why?
| | Protein Kinase C beta | 1 | 2017 | 21 | 0.140 |
Why?
| | Extracellular Matrix | 1 | 2021 | 528 | 0.140 |
Why?
| | Receptors, Adrenergic, alpha-2 | 1 | 2017 | 18 | 0.140 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 9 | 0.130 |
Why?
| | Survival Analysis | 4 | 2021 | 1325 | 0.130 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 19 | 0.130 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 185 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 889 | 0.130 |
Why?
| | Patient Transfer | 1 | 2019 | 176 | 0.130 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 56 | 0.130 |
Why?
| | Galectin 3 | 1 | 2016 | 20 | 0.130 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 786 | 0.130 |
Why?
| | Electrocardiography | 3 | 2015 | 629 | 0.130 |
Why?
| | Vectorcardiography | 1 | 2016 | 5 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 344 | 0.130 |
Why?
| | Cytomegalovirus Infections | 2 | 2025 | 192 | 0.130 |
Why?
| | Adult | 13 | 2024 | 37929 | 0.130 |
Why?
| | Isoenzymes | 1 | 2017 | 304 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 183 | 0.130 |
Why?
| | Self Care | 1 | 2019 | 380 | 0.130 |
Why?
| | Transition to Adult Care | 1 | 2017 | 91 | 0.120 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2017 | 283 | 0.120 |
Why?
| | Research Design | 1 | 2022 | 1139 | 0.120 |
Why?
| | Plasma | 1 | 2018 | 212 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 276 | 0.120 |
Why?
| | Vascular Resistance | 1 | 2017 | 375 | 0.120 |
Why?
| | Perioperative Care | 1 | 2017 | 178 | 0.120 |
Why?
| | Vasoconstriction | 1 | 2017 | 202 | 0.120 |
Why?
| | Exosomes | 1 | 2017 | 103 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 307 | 0.120 |
Why?
| | Incidence | 3 | 2025 | 2804 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 333 | 0.120 |
Why?
| | Mutation | 3 | 2023 | 3958 | 0.120 |
Why?
| | Up-Regulation | 1 | 2018 | 843 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 545 | 0.120 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 82 | 0.120 |
Why?
| | Follow-Up Studies | 7 | 2024 | 5131 | 0.120 |
Why?
| | Ketamine | 1 | 2015 | 94 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.110 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2015 | 89 | 0.110 |
Why?
| | Exercise Test | 3 | 2023 | 625 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 307 | 0.110 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 175 | 0.110 |
Why?
| | Myocardial Contraction | 3 | 2024 | 341 | 0.110 |
Why?
| | Hypoalbuminemia | 1 | 2014 | 30 | 0.110 |
Why?
| | Stroke Volume | 2 | 2016 | 612 | 0.110 |
Why?
| | Coronary Angiography | 1 | 2016 | 317 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1774 | 0.110 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2013 | 11 | 0.110 |
Why?
| | Anthracyclines | 1 | 2013 | 42 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 86 | 0.100 |
Why?
| | Hypnotics and Sedatives | 1 | 2015 | 200 | 0.100 |
Why?
| | Patient Compliance | 1 | 2017 | 581 | 0.100 |
Why?
| | Prognosis | 4 | 2015 | 4030 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 294 | 0.100 |
Why?
| | Vascular Diseases | 1 | 2016 | 243 | 0.100 |
Why?
| | Organ Transplantation | 1 | 2016 | 250 | 0.100 |
Why?
| | Fetal Heart | 1 | 2013 | 55 | 0.100 |
Why?
| | Myosin Heavy Chains | 1 | 2014 | 192 | 0.100 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 47 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2016 | 965 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2017 | 766 | 0.100 |
Why?
| | Tissue and Organ Procurement | 1 | 2016 | 321 | 0.090 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 99 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 182 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 339 | 0.090 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 188 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1066 | 0.090 |
Why?
| | Postoperative Complications | 5 | 2025 | 2654 | 0.090 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2014 | 238 | 0.090 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 173 | 0.090 |
Why?
| | Altitude | 2 | 2021 | 488 | 0.090 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2010 | 67 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 270 | 0.080 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 226 | 0.080 |
Why?
| | United States | 8 | 2024 | 14841 | 0.080 |
Why?
| | Mycoses | 1 | 2010 | 79 | 0.080 |
Why?
| | Patient Selection | 1 | 2014 | 696 | 0.080 |
Why?
| | Air Ambulances | 1 | 2010 | 32 | 0.080 |
Why?
| | RNA | 1 | 2016 | 921 | 0.080 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 416 | 0.080 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 170 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.080 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1457 | 0.080 |
Why?
| | Oxygen Consumption | 2 | 2023 | 696 | 0.080 |
Why?
| | Colorado | 6 | 2017 | 4565 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1329 | 0.080 |
Why?
| | Travel | 1 | 2010 | 130 | 0.080 |
Why?
| | Cohort Studies | 6 | 2015 | 5742 | 0.070 |
Why?
| | Mitral Valve Stenosis | 1 | 2008 | 18 | 0.070 |
Why?
| | Cardiac Surgical Procedures | 2 | 2017 | 530 | 0.070 |
Why?
| | Angioplasty, Balloon | 1 | 2009 | 93 | 0.070 |
Why?
| | Registries | 2 | 2014 | 2035 | 0.070 |
Why?
| | RNA, Transfer, Glu | 1 | 2007 | 6 | 0.070 |
Why?
| | Cell Line | 2 | 2025 | 2847 | 0.070 |
Why?
| | Reoperation | 3 | 2021 | 573 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2021 | 2833 | 0.070 |
Why?
| | Mitochondrial Diseases | 1 | 2007 | 91 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2021 | 1060 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2057 | 0.060 |
Why?
| | Stem Cells | 1 | 2010 | 594 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 338 | 0.060 |
Why?
| | Pregnancy | 2 | 2021 | 6763 | 0.060 |
Why?
| | Stents | 1 | 2009 | 527 | 0.060 |
Why?
| | 3' Untranslated Regions | 1 | 2025 | 145 | 0.060 |
Why?
| | Stroke | 1 | 2012 | 1120 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2024 | 2844 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2025 | 404 | 0.050 |
Why?
| | Echocardiography, Doppler | 1 | 2024 | 108 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 314 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1062 | 0.050 |
Why?
| | Risk | 2 | 2019 | 912 | 0.050 |
Why?
| | Pilot Projects | 2 | 2019 | 1710 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1226 | 0.050 |
Why?
| | Palliative Care | 1 | 2009 | 758 | 0.050 |
Why?
| | Middle Aged | 4 | 2016 | 33479 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 767 | 0.050 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2828 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 17 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 55 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 8 | 0.050 |
Why?
| | Acyltransferases | 1 | 2021 | 57 | 0.050 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 93 | 0.040 |
Why?
| | Serum Response Factor | 1 | 2021 | 33 | 0.040 |
Why?
| | Fetoscopy | 1 | 2021 | 30 | 0.040 |
Why?
| | Genotype | 2 | 2017 | 1916 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1946 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2023 | 279 | 0.040 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 126 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 810 | 0.040 |
Why?
| | Gene Expression | 2 | 2017 | 1502 | 0.040 |
Why?
| | Drainage | 1 | 2021 | 173 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 40 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1509 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 499 | 0.040 |
Why?
| | Recurrence | 2 | 2012 | 1060 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2074 | 0.040 |
Why?
| | Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 285 | 0.040 |
Why?
| | Ventricular Function | 1 | 2019 | 61 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 443 | 0.040 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.040 |
Why?
| | Risk Assessment | 3 | 2016 | 3457 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2017 | 2189 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 730 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2837 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 200 | 0.040 |
Why?
| | Treatment Failure | 2 | 2010 | 356 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 455 | 0.040 |
Why?
| | Neoplasms | 1 | 2013 | 2671 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 158 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1793 | 0.040 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 73 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 816 | 0.040 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 114 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 90 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2025 | 1991 | 0.030 |
Why?
| | Adenoidectomy | 1 | 2017 | 72 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 91 | 0.030 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 57 | 0.030 |
Why?
| | Sampling Studies | 1 | 2016 | 99 | 0.030 |
Why?
| | Observer Variation | 1 | 2017 | 343 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 621 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 85 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 89 | 0.030 |
Why?
| | Brain Death | 1 | 2016 | 46 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 182 | 0.030 |
Why?
| | Autopsy | 1 | 2016 | 95 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1468 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 176 | 0.030 |
Why?
| | Diastole | 1 | 2016 | 149 | 0.030 |
Why?
| | Systole | 1 | 2016 | 189 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4295 | 0.030 |
Why?
| | Italy | 1 | 2015 | 110 | 0.030 |
Why?
| | Markov Chains | 1 | 2015 | 126 | 0.030 |
Why?
| | DNA, Complementary | 1 | 2015 | 272 | 0.030 |
Why?
| | Cardiac Output | 1 | 2015 | 165 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 956 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 771 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 216 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 948 | 0.030 |
Why?
| | Action Potentials | 1 | 2018 | 493 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 176 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 816 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 391 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2015 | 126 | 0.030 |
Why?
| | Public Health | 1 | 2019 | 588 | 0.030 |
Why?
| | Exons | 1 | 2015 | 355 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2016 | 849 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2017 | 248 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 85 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1316 | 0.030 |
Why?
| | Analgesics | 1 | 2015 | 206 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 898 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 827 | 0.030 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 127 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 852 | 0.020 |
Why?
| | Transplant Recipients | 1 | 2014 | 184 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2012 | 59 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 257 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1483 | 0.020 |
Why?
| | Mice | 3 | 2015 | 17787 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2013 | 310 | 0.020 |
Why?
| | Exercise | 1 | 2023 | 2057 | 0.020 |
Why?
| | Pediatrics | 1 | 2019 | 1101 | 0.020 |
Why?
| | Nutritional Status | 1 | 2014 | 350 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1266 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2010 | 269 | 0.020 |
Why?
| | France | 1 | 2010 | 33 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 332 | 0.020 |
Why?
| | Shock, Cardiogenic | 1 | 2010 | 63 | 0.020 |
Why?
| | Body Weight | 1 | 2014 | 985 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 316 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2010 | 165 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2010 | 286 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 98 | 0.020 |
Why?
| | Internationality | 1 | 2010 | 155 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1972 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1287 | 0.020 |
Why?
| | Tricuspid Atresia | 1 | 2008 | 5 | 0.020 |
Why?
| | Venae Cavae | 1 | 2008 | 8 | 0.020 |
Why?
| | Vena Cava, Superior | 1 | 2008 | 23 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 136 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1129 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 518 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2008 | 153 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1272 | 0.020 |
Why?
| | Probability | 1 | 2008 | 304 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 664 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 410 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3284 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2007 | 303 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2008 | 429 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1236 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5778 | 0.010 |
Why?
| | Aged | 2 | 2014 | 23961 | 0.010 |
Why?
| | Length of Stay | 1 | 2008 | 1215 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1996 | 0.010 |
Why?
|
|
Miyamoto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|